[go: up one dir, main page]

GT200900007A - Derivados de purina como agonistas de a2a - Google Patents

Derivados de purina como agonistas de a2a

Info

Publication number
GT200900007A
GT200900007A GT200900007A GT200900007A GT200900007A GT 200900007 A GT200900007 A GT 200900007A GT 200900007 A GT200900007 A GT 200900007A GT 200900007 A GT200900007 A GT 200900007A GT 200900007 A GT200900007 A GT 200900007A
Authority
GT
Guatemala
Prior art keywords
compounds
agonists
purine derivatives
adenosine
sales
Prior art date
Application number
GT200900007A
Other languages
English (en)
Inventor
Fairhurst Robin Alec
Taylor Roger John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900007A publication Critical patent/GT200900007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN TRATA DE COMPUESTOS DE FÓRMULA (I) O LOS ESTEREOISÓMEROS O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE W, R1, R2 Y R3 TIENEN LOS SIGNIFICADOS INDICADOS EN LA MEMORIA DESCRIPTIVA, SON ÚTILES PARA EL TRATAMIENTO DE LAS CONDICIONES MEDIADAS POR LA ACTIVACIÓN DEL RECEPTOR DE ADENOSINA A2A, EN ESPECIAL LAS ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VÍAS RESPIRATORIAS. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS, Y UN PROCESO PARA LA PREPARACIÓN DE LOS COMPUESTOS.
GT200900007A 2006-07-13 2009-01-12 Derivados de purina como agonistas de a2a GT200900007A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06117168A EP1889846A1 (en) 2006-07-13 2006-07-13 Purine derivatives as A2a agonists

Publications (1)

Publication Number Publication Date
GT200900007A true GT200900007A (es) 2009-11-30

Family

ID=37496423

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900007A GT200900007A (es) 2006-07-13 2009-01-12 Derivados de purina como agonistas de a2a

Country Status (20)

Country Link
US (1) US8071565B2 (es)
EP (2) EP1889846A1 (es)
JP (1) JP2009542753A (es)
KR (1) KR20090016017A (es)
CN (1) CN101479267B (es)
AU (1) AU2007271944A1 (es)
BR (1) BRPI0714216A2 (es)
CA (1) CA2656012A1 (es)
CR (1) CR10520A (es)
EC (1) ECSP099063A (es)
ES (1) ES2393931T3 (es)
GT (1) GT200900007A (es)
IL (1) IL196330A0 (es)
MA (1) MA30693B1 (es)
MX (1) MX2009000375A (es)
NO (1) NO20090664L (es)
RU (1) RU2009104764A (es)
TN (1) TNSN08544A1 (es)
WO (1) WO2008006563A1 (es)
ZA (1) ZA200810671B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) * 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
US20100197914A1 (en) * 2007-10-17 2010-08-05 Robin Alec Fairhurst Purine Derivatives as Adenosine Al Receptor Ligands
MY153738A (en) * 2008-09-05 2015-03-13 Acucela Inc Sulphur-linked compounds for treating ophthalmic diseases and disorders.
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
SG11202013216RA (en) 2018-07-05 2021-01-28 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN117069627B (zh) * 2022-10-13 2025-08-26 上海康斯维克生物医药有限公司 4-(3-(3-氨磺酰基苯基)脲基)丁酸化合物、其荧光标记物、制备方法及用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) 1986-07-10 1989-10-10 Board Of Governors Of Wayne State University Process for the preparation of cyclopentanoids and novel intermediates produced thereby
IL84414A0 (en) 1986-11-14 1988-04-29 Ciba Geigy Ag N9-cyclopentyl-substituted adenine derivatives
US4954504A (en) 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
JP2586897B2 (ja) 1987-03-09 1997-03-05 富士薬品工業株式会社 光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
DE69123974T2 (de) 1990-09-25 1997-05-07 Rhone-Poulenc Rorer International (Holdings) Inc., Greenville, Del. Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
EP0909270B1 (en) 1996-01-02 2002-06-26 Aventis Pharmaceuticals Products Inc. Process for preparing 2,4-dihydroxypyridine and 2,4-dihydroxy-3-nitropyridine
US6376472B1 (en) 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AU750322B2 (en) 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AP2000002016A0 (en) * 1998-06-23 2000-12-31 Glaxo Group Ltd 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives.
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
BR9914526A (pt) 1998-10-16 2001-07-03 Pfizer Derivados de adenina
JP2002534430A (ja) 1998-12-31 2002-10-15 アベンティス・ファーマスーティカルズ・プロダクツ・インコーポレイテツド Ｎ６−置換デアザアデノシン誘導体類の製造法
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0022695D0 (en) * 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
CA2434906C (en) 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
GB2372741A (en) 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US20090170803A1 (en) 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
WO2005063246A1 (en) 2003-12-29 2005-07-14 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
US20080221060A1 (en) 2004-03-05 2008-09-11 Martyn Pritchard Therapeutic Compounds
WO2005107463A1 (en) 2004-05-03 2005-11-17 University Of Virginia Patent Foundation Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
EP1778239B1 (en) 2004-07-28 2013-08-21 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
AU2005285284B2 (en) 2004-09-09 2011-06-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 and A1 adenosine receptor agonists
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20080051364A1 (en) 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CA2596424C (en) 2005-02-04 2016-03-29 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2622879C (en) 2005-11-30 2011-07-05 Can-Fite Biopharma Ltd. Use of a3 adenosine receptor agonist in osteoarthritis treatment
ES2360632T3 (es) 2006-01-26 2011-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Moduladores alostéricos del receptor a3 de adenosina.
CN110003216A (zh) 2006-02-02 2019-07-12 千禧药品公司 E1活化酶抑制剂
US20080027022A1 (en) 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
WO2008124150A1 (en) 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
US8153781B2 (en) 2007-06-29 2012-04-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
US20100197914A1 (en) * 2007-10-17 2010-08-05 Robin Alec Fairhurst Purine Derivatives as Adenosine Al Receptor Ligands
US20090181934A1 (en) 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
WO2009061516A1 (en) 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
US20090181920A1 (en) 2008-01-09 2009-07-16 Pgxhealth, Llc Intrathecal treatment of neuropathic pain with a2ar agonists

Also Published As

Publication number Publication date
EP2044070A1 (en) 2009-04-08
WO2008006563A1 (en) 2008-01-17
US8071565B2 (en) 2011-12-06
NO20090664L (no) 2009-02-11
US20100240680A1 (en) 2010-09-23
TNSN08544A1 (en) 2010-04-14
EP2044070B1 (en) 2012-08-22
BRPI0714216A2 (pt) 2013-01-29
MA30693B1 (fr) 2009-09-01
JP2009542753A (ja) 2009-12-03
KR20090016017A (ko) 2009-02-12
CR10520A (es) 2009-03-19
AU2007271944A1 (en) 2008-01-17
ES2393931T3 (es) 2013-01-02
ZA200810671B (en) 2009-11-25
RU2009104764A (ru) 2010-08-20
EP1889846A1 (en) 2008-02-20
ECSP099063A (es) 2009-02-27
IL196330A0 (en) 2009-09-22
CA2656012A1 (en) 2008-01-17
CN101479267B (zh) 2012-05-02
MX2009000375A (es) 2009-01-27
CN101479267A (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
GT200900007A (es) Derivados de purina como agonistas de a2a
CR10621A (es) Derivados de adenosina como agonistas del receptor a2a
GT200800219A (es) Derivados de purina para utilizarse como agonistas del receptor de adenosina a2a
ECSP077404A (es) Derivados de purina para usarse como agonistas de receptores a-2a de adenosina
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
PE20220387A1 (es) Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer
NI201000145A (es) DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
NI201300107A (es) Derivados de nucleósidos 2' - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales.
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
PA8825301A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
GT200600013A (es) Compuestos organicos
UY30547A1 (es) Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones.
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
NO20085257L (no) Purinonderivater som HM74a-agonister
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
NO20085099L (no) Puritonderivativer som HM74A agonister
UY30282A1 (es) Compuestos quimicos